Aldeyra Therapeutics (ALDX) Enterprise Value (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Enterprise Value of -$40.9 million for Q1 2026, up 41.67% on a QoQ basis from -$70.0 million in Q4 2025, and up 54.64% year-over-year from -$26.4 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Enterprise Value (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Enterprise Value history runs 14 years deep, the most recent figure standing at -$40.9 million for Q1 2026.
- Quarterly Enterprise Value rose 54.64% year-over-year to -$40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.9 million (up 54.64% YoY) and the FY2025 annual result came in at -$70.0 million, up 30.76% from the prior year.
- Enterprise Value was -$40.9 million for Q1 2026 at Aldeyra Therapeutics, up from -$70.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$14.3 million in Q4 2023 and bottomed at -$174.3 million in Q4 2022.
- A 5-year average of -$108.0 million and a median of -$101.2 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 91.79% — and 2024, when it slumped 606.73%.
- Aldeyra Therapeutics' Enterprise Value stood at -$174.3 million in 2022, then soared by 91.79% to -$14.3 million in 2023, then slumped by 606.73% to -$101.2 million in 2024, then soared by 30.76% to -$70.0 million in 2025, then soared by 41.67% to -$40.9 million in 2026.
- Business Quant data shows ALDX's Enterprise Value at -$40.9 million in Q1 2026, -$70.0 million in Q4 2025, and -$70.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | -40.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.85 Mn |
| Dec 31, 2025 | -70.04 Mn |
| Sep 30, 2025 | -70.94 Mn |
| Jun 30, 2025 | -81.92 Mn |
| Mar 31, 2025 | -90.06 Mn |
| Dec 31, 2024 | -101.15 Mn |
| Sep 30, 2024 | -72.74 Mn |
| Jun 30, 2024 | -80.33 Mn |
| Mar 31, 2024 | -146.02 Mn |
| Dec 31, 2023 | -14.31 Mn |
| Sep 30, 2023 | -143.33 Mn |
| Jun 30, 2023 | -151.68 Mn |
| Mar 31, 2023 | -165.03 Mn |
| Dec 31, 2022 | -174.30 Mn |
| Sep 30, 2022 | -163.83 Mn |
| Jun 30, 2022 | -117.69 Mn |
| Mar 31, 2022 | -151.87 Mn |
| Dec 31, 2021 | -129.43 Mn |
| Sep 30, 2021 | -116.37 Mn |
| Jun 30, 2021 | -124.74 Mn |